REpAb® Anti-Idiotype Antibody Discovery.
Functionally enriched discovery powered by REpAb® Sequencing.
Targeted Anti-Idiotype Antibody Discovery.
How It Works.
Anti-idiotype antibodies (Ab2) are critical tools for pharmacokinetic studies, immunogenicity assessment, and drug monitoring assays. However, their discovery is technically challenging due to the need for extreme specificity to therapeutic antibodies while minimizing cross-reactivity with endogenous IgGs.
Rapid Novor’s Anti-Idiotype Antibody Discovery workflow applies functional enrichment prior to sequencing, enabling precise identification of high-affinity, low-background binders using our REpAb® mass spectrometry-based antibody sequencing platform.
REpAb® Platform Capabilities.
Application Note: Functional Anti-Idiotype Discovery
Adalimumab was selected as a model therapeutic antibody due to the stringent requirement for variable-region specificity while avoiding cross-reactivity with endogenous human IgG. Starting from an adalimumab-immunized rabbit, functional enrichment of immunoserum yielded an antigen-enriched IgG polyclonal anti-idiotype population. REpAb® sequencing identified 23 antibody groups based on CDR3 similarity, spanning all three anti-idiotype subtypes (non-blocking, blocking, and partially blocking).
Our recombinantly expressed antibodies showed higher affinity for adalimumab than commercial reagents, low non-specific human IgG binding, and were successfully applied to patient serum profiling in pharmacokinetic studies. This case study demonstrates how functional enrichment combined with REpAb® sequencing enables rapid discovery of high-affinity, subtype-resolved anti-idiotype antibodies directly from immunoserum, supporting downstream recombinant, animal-free production.
Getting Started.
Deliverables
- Full-length, antigen-specific monoclonal antibody sequences with confidence metrics through peptide datasets.
- Abundance and ranking data to prioritize leads.
- Recombinant expression constructs and expression data (optional).
- Biophysical characterization of recombinant antibodies (optional).
- Technical report summarizing methods, results, and recommended candidates.
Turn-Around Time
Applications
REpAb® Anti-Idiotypic Antibody Discovery is suitable for:
- PK and ADA assay development
- Therapeutic drug monitoring
- Bioanalytical method development
- Mechanistic studies of antibody therapeutics
More on How REpAb® Works.
REpAb® is a proprietary platform designed to reconstruct monoclonal antibodies directly from serum, providing an unparalleled window into the functional humoral immune response. By integrating advanced proteomic, genomic, and structural approaches, REpAb® enables the discovery of clinically relevant antibodies that might be missed using conventional methods.
The REpAb® workflow begins with enrichment of antibodies directly from serum. Using highly specific antigen probes, layers of positive selection, and negative depletion, anti-idiotypic polyclonal IgG is captured from the complex serum mixture, ensuring that only antibodies with functional relevance to the target antigen are analyzed. This approach isolates naturally affinity-matured antibodies without the need for B cell sorting, capturing the true physiological repertoire of circulating antibodies.
high-resolution mass spectrometry, enabling de novo sequencing of peptides, through our proprietary software. This allows REpAb® to reconstruct the amino acid sequences of individual monoclonal antibodies from complex polyclonal pools, even when the heavy and light chain pairing is not initially known.
Key capabilities include:
- Identification of CDR, framework, and constant region amino acid sequences.
- Reconstruction of complete monoclonal antibody sequences, including heavy and light chain pairing.
- Cross-referencesMS data with Ig-sequencing, prioritizing high-confidence sequences.
- ELISA or other binding assays to confirm target specificity.
- Ranking of candidates by abundance, sequence quality, or functional metrics.
- Surface Plasmon Resonance (SPR)
- Epitope binning
- Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS)
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics
Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.
Talk to Our Scientists.
Antibody Discovery, Directly.
Skip the guesswork: begin with a functionally validated antibody mixture, not just sequences or cells. Contact us.
The Science of Antibody Discovery.
Antibody Sequencing & Discovery Services.
Antibody Sequencing, Discovery and Characterization Services.
Antibody Sequencing & Discovery Services.
REmAb® mAb Sequencing
Monoclonal antibody sequencing from small antibody samples, no need for hybridoma or DNA information. Full sequence in record time.
Explore Antibody Sequencing Services
REpAb® pAb Sequencing
Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Explore Antibody Discovery Services
RapidSPR™ Analysis
Label-free evaluation of antibody-antigen binding using surface plasmon resonance on Biacore or Nicoya. Can be employed for detailed kinetic profiling, kinetics screening, or epitope binning.
Explore SPR Services
RapidHDX-MS™
Mass spec based epitope mapping. Epitope mapping for identify the binding site of an antibody to its corresponding antigen with the highest confidence and resolution.
Explore HDX-MS Epitope Mapping Service
MATCHmAb™
Antibody verification by rapid peptide mapping. Antibody sequence confirmation and full detailed mapping for development purposes.
Explore Peptide Mapping Service
Antibody Characterization
LC-MS analysis for study of antibody glycosylation, disulfide bonds, post-translational modifications, sequence variants, intact mass and size.
Explore Antibody Characterization Services